BioWorld

July 31, 2007

Vivus Gains Evamist Approval, $140M Payment From Partner

Vivus Inc. won FDA approval of its Evamist product, triggering a $140 million milestone payment from a partnership entered earlier this year. (BioWorld Today) Read More

Plasma-Based Drug Firm Talecris Seeking $1B IPO

ImClone, BMS Pump Cash Into Erbitux For Broad Label

Alnylam, Medtronic Expand Deal With RNAi Drug-Device Combos

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 15, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 16, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of brain with electrical activity background

ABS-1230 controls seizures in KCNT1-driven severe epilepsy

BioWorld Science

Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...